Patent application number | Description | Published |
20080200799 | Mri Involving Contrast Agent With Time Modulated Contrast Enhancement - The present invention provides a method MRI imaging. By applying a time modulation to the contrast enhancement of an MRI contrast agent, the method according to the invention leads to images with improved signal-to-noise ratio in the contrast-enhanced areas, strongly suppressed unwanted signal in the unenhanced areas, and reduced artefacts, such as motion artefacts. | 08-21-2008 |
20080257021 | Method of Making Dried Particles - A method is provided that prepares resuspendable particles of a compound. The particles are prepared by drying a liquid that comprises the compound. The particles are dried in such a way that they do not aggregate on redispersion. The particles that are thus obtained are especially suitable for use in bio sensors, as contrast agent or as part of a pharmaceutical composition. | 10-23-2008 |
20080258726 | Distinguishing Bound and Unbound Contrast Agents Using Magnetic Resonance - Magnetic resonance monitoring of a target ( | 10-23-2008 |
20080267878 | Targeted Imaging And/Or Therapy Using The [3+2] Azide-Alkyne Cycloaddition - The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the [3+2] cycloaddition, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations. | 10-30-2008 |
20080274057 | Staudinger Reaction in Imaging and Therapy and Kits for Use in Imaging and Therapy - The Staudinger reaction can be used for activation of prodrugs or pro-imaging probes. The invention relates to a method of preparing and activating prodrugs or pro-imaging probes by using the Staudinger reaction and to kits for medical imaging and/or therapy comprising at least one prodrug and/or pro-imaging probe comprising at least one azide and/or phosphine group. | 11-06-2008 |
20090123385 | PREPARATION OF DISPERSIONS OF PARTICLES FOR USE AS CONTRAST AGENTS IN ULTRASOUND IMAGING - A method of making a suspension of particles in a first fluid of a size suitable for responding to ultrasound, by forcing a second fluid ( | 05-14-2009 |
20090196830 | ELIMINATION OF CONTRAST AGENT CONCENTRATION DEPENDENCY IN MRI - The present invention relates to a method for MRI imaging to obtain information about a local physiochemical parameter after administration to a patient of a contrast agent comprising at least one non-responsive contrast enhancing entity that does not occur naturally in a human body and at least one responsive contrast enhancing entity attached to or mixed with the non-responsive contrast enhancing entity. By using such non-responsive contrast enhancing entities, a value for the physicochemical parameter can be obtained by acquiring only three images through which the method according to the present invention will be easier to apply in clinical routine since it will be faster and less sensitive to motion or flow artefacts. | 08-06-2009 |
20100054570 | MOTION CORRECTED MULTINUCLEAR MAGNETIC RESONANCE IMAGING - The invention relates to a method for acquiring MR images ( | 03-04-2010 |
20100247445 | POLYMERIC DRUG CARRIER FOR IMAGE-GUIDED DELIVERY - Described are Chemical Exchange-dependent Saturation Transfer (CEST) contrast agents for Magnetic Resonance Imaging (MRI) comprising a polymersome provided with a paramagnetic agent. The polymersome preferably comprises a polymeric shell enclosing a cavity, wherein the cavity comprises a pool of proton analytes, and wherein the shell allows diffusion of the proton analytes. The polymersome-based CEST MRI contrast agents are suitable as drug carriers useful in MRI-guided drug release. | 09-30-2010 |
20110177009 | DRUG CARRIER PROVIDING MRI CONTRAST ENHANCEMENT - Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a | 07-21-2011 |
20110182821 | CLUSTERED MAGNETIC PARTICLES AS TRACERS FOR MAGNETIC PARTICLE IMAGING - The invention provides a magnetic tracer material for use in magnetic particle imaging and a manufacturing method thereof. The magnetic tracer material comprises clusters of a plurality of magnetic particles that are clustered in a controlled way to form individual entities, for example, stabilized oil droplets, solid emulsion particles, liposomes, polymersomes or vesicles, or naturally occurring biological entities such as cells or viruses. | 07-28-2011 |
20110288402 | MR IMAGING WITH CEST CONTRAST ENHANCEMENT - The invention relates to a method of MR imaging of at least a portion of a body of a patient placed in an examination volume of an MR device. The object of the invention is to improve CEST contrast enhanced imaging. The method of the invention comprises the following steps: a) saturation of nuclear magnetization of exchangeable protons of a CEST contrast agent administered to the patient by subjecting the portion of the body to at least one frequency-selective saturation RF pulse matched to the MR frequency of exchangeable protons of the CEST contrast agent, wherein the saturation period, i.e. the duration of the frequency-selective saturation RF pulse, is shorter than the time required for saturation to build up a full CEST contrast enhancement effect when starting from zero saturation; b) generating at least one MR signal of water protons of the body by subjecting the portion of the body to an MR imaging sequence comprising at least one RF pulse and switched magnetic field gradients; c) acquiring sampling the at least one MR signal from the body; d) repeating steps a) to c) a number of times under variation of parameters of the MR imaging sequence, wherein MR signals are acquired and sampled during a saturation build-up period, i.e. before a steady state of the CEST effect is achieved; e) reconstructing a proton-density weighted, CEST contrast-enhanced MR image from the acquired and sampled MR signals. | 11-24-2011 |
20120100079 | STIMULI-RESPONSIVE CARRIERS FOR MPI-GUIDED DRUG DELIVERY - The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least −18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these. The present invention further relates to the use of such a composition or a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent, wherein said contrast agent is capable of being detected by MPI and wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus as a carrier for a controlled delivery of a drug, as well as to a method of data acquisition for the control of a drug delivery process comprising the detection or localization via MPI of such compositions. In a further aspect the present invention relates to such compositions for treating a pathological condition, wherein the treatment comprises the release of the drug by the application of a stimulus. | 04-26-2012 |
20120128589 | Perfluoro Compounds For Use In Imaging - Described is the use of perfluoro-t-butyl cyclohexane in a contrast agent for molecular imaging, notably F MRI. Particularly, the perfluoro-t-butyl cyclohexane is present in the form of an aqueous emulsion of nanoparticles comprising the perfluoro compound as a core, and an emulsifying agent, such as a phospholipid, as a shell. The shell can be functionalized with other moieties that play a role in imaging, notably ligands for targeted binding and/or contrast agents or labels with a view to other imaging modalities. The latter particularly refers to | 05-24-2012 |
20130108551 | LIPID BILAYER CARRIER FOR DRUGS OR IMAGING AGENTS | 05-02-2013 |
20130302253 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS - Disclosed is a carrier for the local, targeted administration of a hydrophobic drug. The hydrophobic drug is rendered in to a hydrophilic prodrug thereof, and is contained in the lumen of a thermosensitive liposome or polymersome. Upon administration of the carrier, heat can be applied at the locus where the drug is to be released. After release of the prodrug, it will be activated so as to turn into the active drug. | 11-14-2013 |
20140127135 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF - Disclosed are lipidomimetic compounds of formula I (I) wherein: G represents a group satisfying formula II: HO—CH | 05-08-2014 |